S Cavalheiro1, P A Dastoli, N S Silva, S Toledo, H Lederman, M C da Silva. 1. Department of Neurology and Neurosurgery, Pediatric Oncology Institute, Federal University of São Paulo-Escola Paulista de Medicina, Rua Botucatu 591/42, 4023-061, São Paulo, Brazil. iscava@uol.com.br
Abstract
OBJECTIVES: This study analyzed the intratumoral activity of interferon alpha (IFN-alpha) in the treatment of cystic craniopharyngiomas. PATIENTS AND METHODS: From January 2000 to January 2004, nine patients presenting with cystic craniopharyngiomas were treated with intratumoral injection of IFN-alpha at the Pediatric Oncology Institute of the Federal University of São Paulo-Escola Paulista de Medicina. Age ranged from 1 year and 10 months to 18 years (mean 10 years). All intratumoral catheters were inserted by a subfrontal approach. Doses varied from 36 to 108 MU. RESULTS: There was complete disappearance of the lesion in seven cases. In two cases, partial reduction of tumor size was observed at follow-up. Follow-up varied from 1 year to 3 years and 6 months (mean 1 year 8 months). CONCLUSIONS: IFN-alpha proved to be an effective drug in the control of cystic craniopharyngiomas. Additional studies should be carried out to determine the optimal dose of IFN-alpha in the treatment of cystic craniopharyngioma. In addition, other drugs possessing high efficacy and low neurotoxicity should be analyzed.
OBJECTIVES: This study analyzed the intratumoral activity of interferon alpha (IFN-alpha) in the treatment of cystic craniopharyngiomas. PATIENTS AND METHODS: From January 2000 to January 2004, nine patients presenting with cystic craniopharyngiomas were treated with intratumoral injection of IFN-alpha at the Pediatric Oncology Institute of the Federal University of São Paulo-Escola Paulista de Medicina. Age ranged from 1 year and 10 months to 18 years (mean 10 years). All intratumoral catheters were inserted by a subfrontal approach. Doses varied from 36 to 108 MU. RESULTS: There was complete disappearance of the lesion in seven cases. In two cases, partial reduction of tumor size was observed at follow-up. Follow-up varied from 1 year to 3 years and 6 months (mean 1 year 8 months). CONCLUSIONS:IFN-alpha proved to be an effective drug in the control of cystic craniopharyngiomas. Additional studies should be carried out to determine the optimal dose of IFN-alpha in the treatment of cystic craniopharyngioma. In addition, other drugs possessing high efficacy and low neurotoxicity should be analyzed.
Authors: R I Jakacki; B H Cohen; C Jamison; V P Mathews; E Arenson; D C Longee; J Hilden; A Cornelius; M Needle; D Heilman; J C Boaz; T G Luerssen Journal: J Neurosurg Date: 2000-02 Impact factor: 5.115
Authors: C Selleri; T Sato; L Del Vecchio; L Luciano; A J Barrett; B Rotoli; N S Young; J P Maciejewski Journal: Blood Date: 1997-02-01 Impact factor: 22.113
Authors: Abd El Rahman Enayet; Mostafa M E Atteya; Hala Taha; Mohamed Saad Zaghloul; Amal Refaat; Eslam Maher; Amal Abdelaziz; Mohamed A El Beltagy Journal: Childs Nerv Syst Date: 2020-07-26 Impact factor: 1.475
Authors: Philipp Kickingereder; Mohammad Maarouf; Faycal El Majdoub; Manuel Fuetsch; Ralph Lehrke; Jochen Wirths; Klaus Luyken; Klaus Schomaecker; Harald Treuer; Juergen Voges; Volker Sturm Journal: J Neurooncol Date: 2012-06-21 Impact factor: 4.130
Authors: D F Ierardi; M J S Fernandes; I R Silva; J Thomazini-Gouveia; N S Silva; P Dastoli; S R C Toledo; S Cavalheiro Journal: Childs Nerv Syst Date: 2007-06-26 Impact factor: 1.475